Restorbio, an aging-related disease drug developer co-founded by PureTech Health, also counts Novartis as a shareholder.
Pharmaceutical firm Novartis is set to achieve an exit from Restorbio, a US-based aging-related disease therapy developer that has filed to raise up to $85m in an initial public offering.
Co-founded in 2016 by biopharmaceutical company PureTech Health, Restorbio is working on treatments for several aging-related conditions related to the decline in the body’s immune system which have no approved cure in the US, including respiratory tract infections (RTIs).
Development of the company’s lead product candidate, a small-molecule inhibitor…
